SymBio PharmaceuticalsSymBio Pharmaceuticals Limited4582東証グロース医薬品FY ending Dec 2025, consolidated, J-GAAP
It lost about ¥340 for every ¥100 of sales at the operating level. Revenue changed -46.7% from the prior year.
Net margin × asset turnover = ROA; ROA × financial leverage = ROE
| Period | Net margin | Asset turnover | ROA | Financial leverage | ROE |
|---|---|---|---|---|---|
| 2021 | 24.6% | 0.98× | 24.0% | 1.36× | 32.6% |
| 2022 | 11.8% | 0.96× | 11.3% | 1.29× | 14.6% |
| 2023 | — | —× | -21.1% | —× | — |
| 2024 | — | —× | -58.4% | —× | — |
| 2025 | — | —× | -108.1% | —× | — |
Financial leverage can raise ROE; a higher value alone does not describe a company's overall condition.
Annual trends in tangible-asset ratios and goodwill balance.
Ratios are derived from reported values. Goodwill is shown only when separately reported; it is not inferred from combined intangible assets. Definition
Track R&D investment and how long operating capital remains tied up before sales turn into cash.
R&D is shown only for years with machine-readable disclosure. Days are estimates using year-end receivables, inventory and payables divided by annual revenue or cost of sales; financial companies are excluded.
| Item | FY ending Dec 2021 | FY ending Dec 2022 | FY ending Dec 2023 | FY ending Dec 2024 | FY ending Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 8,257 | 10,008 | 5,590 | 2,453 | 1,308 |
| Cost of revenue | 2,452 | 2,408 | 1,179 | 580 | 360 |
| Gross profit | 5,804 | 7,600 | 4,411 | 1,873 | 947 |
| SG&A | 4,784 | 5,636 | 5,223 | 5,750 | 5,388 |
| Operating income | 1,016 | 1,964 | -812 | -3,877 | -4,441 |
| Pretax income | 1,001 | 2,106 | -1,195 | -3,807 | -4,749 |
| Income tax | -1,031 | 927 | 767 | 27 | 28 |
| Net income attributable to owners | 2,032 | 1,179 | -1,963 | -3,833 | -4,776 |
| Operating margin | 12.3% | 19.6% | -14.5% | -158.1% | -339.6% |
Year-end figures from filings. Unreported items are omitted. Interest-bearing debt excludes lease liabilities.
Each bar totals 100% of assets; other is the residual.
| Item | FY ending Dec 2021 | FY ending Dec 2022 | FY ending Dec 2023 | FY ending Dec 2024 | FY ending Dec 2025 |
|---|---|---|---|---|---|
| Cash and equivalents | ¥3.86B | ¥6.28B | ¥6.52B | ¥3.96B | ¥2.88B |
| Total assets | ¥8.45B | ¥10.4B | ¥8.17B | ¥4.97B | ¥3.87B |
| Net assets | ¥6.75B | ¥8.51B | ¥7.21B | ¥4.2B | ¥1.27B |
| Share capital | ¥17.2B | ¥17.5B | ¥18B | ¥18.3B | ¥19.2B |
| Property, plant and equipment | ¥83.6M | ¥69M | — | — | — |
| Intangible assets excluding goodwill | ¥259.1M | ¥222.2M | — | — | — |
| Current assets | ¥6.75B | ¥9.31B | ¥8.08B | ¥4.92B | ¥3.82B |
| Current liabilities | ¥1.52B | ¥1.92B | ¥956.6M | ¥766.2M | ¥1.29B |
| Total liabilities | ¥1.71B | ¥1.93B | ¥960.3M | ¥770.8M | ¥2.6B |
| Equity attributable to owners of parent | ¥6.23B | ¥8.09B | ¥6.94B | ¥3.87B | ¥911.2M |
| Retained earnings | -¥28B | -¥26.9B | -¥28.9B | -¥32.7B | -¥37.5B |
| Treasury stock | -¥86M | -¥88.2M | -¥89.1M | -¥89.9M | -¥89.9M |
EDINET (FSA Japan)
有価証券報告書－第21期(2025/01/01－2025/12/31)
EDINET (FSA Japan)
有価証券報告書－第20期(2024/01/01－2024/12/31)
EDINET (FSA Japan)
有価証券報告書－第19期(2023/01/01－2023/12/31)
EDINET (FSA Japan)
訂正有価証券報告書－第18期(2022/01/01－2022/12/31)
EDINET (FSA Japan)
有価証券報告書－第17期(令和3年1月1日－令和3年12月31日)
EDINET (FSA Japan)
有価証券報告書－第16期(令和2年1月1日－令和2年12月31日)
Extracted from XBRL: 40
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.